<DOC>
	<DOCNO>NCT01458301</DOCNO>
	<brief_summary>The purpose study determine efficacy safety TAK-385 , daily ( QD ) , 12 week woman endometriosis .</brief_summary>
	<brief_title>Efficacy Safety TAK-385 Treatment Endometriosis</brief_title>
	<detailed_description>This Phase II , multicenter , double-blind , randomize , parallel-group , placebo-controlled study evaluate efficacy safety 3 dose level ( 10 , 20 , 40 mg ) TAK-385 follow oral administration 12 week woman endometriosis .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . Premenopausal woman 2 . The participant must dysmenorrhea pelvic pain associate endometriosis . 3 . The participant experience regular menstrual cycle . 4 . The participant diagnose endometriosis method ) , b ) , c ) . Laparotomy Laparoscopy Chocolate cyst ovary confirm MRI 1 . Participants diagnose measurable uterine fibroid long diameter 3 cm large 2 . Participants low abdominal pain due irritable bowel syndrome severe interstitial cystitis 3 . Participants previous current history thyroid dysfunction 4 . Participants current previous history pelvic inflammatory disease 5 . Participants positive PAP smear test result conduct 6 . Participants history panhysterectomy bilateral oophorectomy 7 . Participants judge investigator mark abnormal uterine bleed anovulatory bleed 8 . Participants previous current history malignant tumor 9 . Participants treat follow drug : anticoagulant drug , antiplatelet drug , tranexamic acid , selective estrogen receptor modulator ( SERM ) , activate vitamin D , vitamin D , calcitonin , ipriflavone , steroid hormone , vitamin K , teriparatide , denosumab 10 . Participants treat follow drug : oral contraceptive sex hormone preparation , gonadotropinreleasing hormone ( GnRH ) analogue , dienogest , danazol , aromatase inhibitor 11 . Participants treat bisphosphonate preparation 12 . Participants previous current history hypersensitivity allergy Leuplin , synthetic LHRH , LHRH derivative , gelatincontaining formulation food contain gelatin , previous current history severe hypersensitivity severe allergy drug 13 . Participants nondiagnosable abnormal genital bleed 14 . Participants previous current history osteoporosis , bone mass loss , metabolic bone diseases 15 . Participants clinically significant cardiovascular disease uncontrollable hypertension 16 . Participants judge investigator inappropriate participate study base 12lead electrocardiogram ( ECG ) find 17 . Participants active liver disease jaundice , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin &gt; 1.5 time upper limit normal ( ULN ) clinical laboratory test</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>